Ligand Pharmaceuticals Incorporated - Common Stock (LGND) stock analysis

LGND · Ligand Pharmaceuticals Incorporated - Common Stock

Latest recorded price: USD 301.71

Sector and industry: Healthcare · Biotechnology

A reliable intrinsic value could not be calculated for LGND; the assessment relies on sector multiple comparisons. Fiscal 2025 figures: revenue growth 11.0%, free cash flow margin 18.2%, ROIC 1.9%. The model flags 1 risk signal for this company.

Similar companies in Healthcare